Citation Impact
Citing Papers
New approaches and procedures for cancer treatment: Current perspectives
2021 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
1999
Breast cancer
2019 Standout
The relationship between prognostic and predictive factors in the management of breast cancer
1998
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma
2003 StandoutNobel
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Why do cancers have high aerobic glycolysis?
2004 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Molecular imaging in drug development
2008 Standout
Cardiac Toxicity Following Thoracic Radiation
2005
Partial irradiation of the heart
2001
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
2009 Standout
Monitoring response to therapy in cancer using [ 18 F]-2-fluoro-2-deoxy- d -glucose and positron emission tomography: an overview of different analytical methods
2000
The management of respiratory motion in radiation oncology report of AAPM Task Group 76a)
2006 Standout
The role of porphyrin chemistry in tumor imaging and photodynamic therapy
2010 Standout
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Monitoring chemotherapy and radiotherapy of solid tumors
2006
p53, the Cellular Gatekeeper for Growth and Division
1997 Standout
TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast Cancer
2000
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs)
2002
PET and [18F]-FDG in oncology: A clinical update
1996
Imaging in the era of molecular oncology
2008 StandoutNature
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
2007
Esophageal Cancer
2003 Standout
Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response
2014
The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy
1999
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
HPV-associated head and neck cancer: a virus-related cancer epidemic
2010 Standout
Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010
2010 Standout
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Variability in target volume delineation on CT scans of the breast
2001
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
1996
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography
2001
Cancer and Radiation Therapy: Current Advances and Future Directions
2012 Standout
Death and anti-death: tumour resistance to apoptosis
2002 Standout
Molecular portraits of human breast tumours
2000 StandoutNature
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
1999
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy
1996
The Ki-67 protein: From the known and the unknown
2000 Standout
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial
2004
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Measuring [18F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods
2003
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
F-18 FDG Uptake in Breast Infection and Inflammation
2000
The first 30 years of p53: growing ever more complex
2009 Standout
No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
1998
Integrating cell-signalling pathways with NF-κB and IKK function
2006 Standout
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002 StandoutNobel
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy
2006
Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial
2003
Positron Emission Tomography Using [18F]-Fluorodeoxy-d -Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy
2000
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Positron Emission Tomography As an Imaging Biomarker
2006
Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
2000
Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations
2000
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
2000
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.
2004
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
1998
Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.
2002
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002
Reproducibility of metabolic measurements in malignant tumors using FDG PET.
1999
Putting the Rap on Akt
2004
Drug Resistance in Cancer: An Overview
2014 Standout
Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
2003
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
1999 Standout
FDG-PET and Beyond: Molecular Breast Cancer Imaging
2005
Primary Systemic Therapy of Breast Cancer
2006
Radiolabeled amino acids: basic aspects and clinical applications in oncology.
2001
Works of T. Jansson being referenced
Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?
1995
Radiotherapy of breast cancer after breast-conserving surgery: an improved technique using mixed electron–photon beams with a multileaf collimator
1998
p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings.
1995